Bullfrog AI announces white paper on smarter drug development

BullFrog AI (BFRG) Holdings announced the release of a new white paper titled “Why Drug Discovery Fails and How AI is Changing the Equation.” The publication offers a compelling critique of conventional approaches to biopharma R&D-where nearly 90% of drug candidates still fail in clinical trials-and outlines a forward-looking, biology-native AI framework designed to reverse that trend. At the center of this new blueprint is bfLEAP, BullFrog AI’s proprietary platform engineered specifically to account for the complexity, dimensionality, and biological nuance of therapeutic development. “Too much of today’s drug development is driven by black-box algorithms and intuition,” said Vin Singh, Founder and CEO of BullFrog AI. “Our white paper makes the case that it’s time to rethink the way the industry approaches R&D. We need AI that’s built for biology, grounded in causality, and transparent in its conclusions. That’s exactly what bfLEAP delivers.”